TNFRSF10A and neoplasm: Recombinant soluble TRAIL is attractive as an antitumor agent due to its selective apoptosis induction in tumor cells overexpressing TRAIL receptors (death receptor 4, DR4, and death receptor 5, DR5) without systemic toxicity.